Nektar Therapeutics

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$11,175
$10,460
$29,175
$24,124
Gross Profit
10,961
10,460
21,198
19,689
EBITDA
-36,230
-40,969
17,487
-30,035
EBIT
-36,444
-41,395
17,155
-31,028
Net Income
-41,593
-50,882
7,261
-37,057
Net Change In Cash
11,175
10,460
29,175
24,124
Free Cash Flow
-45,775
-49,055
-46,646
-44,598
Cash
42,988
38,894
44,252
30,109
Basic Shares
14,087
14,061
14,239
13,949

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$98,427
$90,122
$92,055
$101,907
Gross Profit
67,741
53,478
70,420
77,010
EBITDA
-86,697
-243,107
-323,872
-462,967
EBIT
-91,088
-250,922
-336,072
-475,967
Net Income
-118,961
-276,056
-368,198
-523,837
Net Change In Cash
98,427
90,122
92,055
101,907
Cost of Revenue
-173,645
Free Cash Flow
-177,177
-193,471
-309,683
-427,649
Cash
44,252
35,277
88,227
25,218
Basic Shares
13,710
12,666
12,475
12,219

Earnings Calls

Quarter EPS
2025-06-30
-$2.78
2025-03-31
-$0.24
2024-12-31
-$0.15
2024-09-30
-$0.18